Literature DB >> 2703003

The association between anatomic site and survival in malignant melanoma. An analysis of 12,353 cases from the Swedish Cancer Registry.

M Thörn1, H O Adami, U Ringborg, R Bergström, U Krusemo.   

Abstract

The relationship between site and survival in cutaneous malignant melanoma was investigated by a follow-up of 12,353 Swedish patients diagnosed in 1960-1982. In males, the poorest prognosis was found for tumors located on the scalp-neck region (5-year relative survival rate, RS51%), followed by the lower extremity (RS66%) and trunk (RS68%). Among females, the poorest prognosis was noted for tumors located on the external ear (5-year RS 71%), trunk (RS 78%) and scalp-neck (RS 78%). The prognosis varied considerably between the sites of the head-neck region--for eyelid and facial lesions the prognosis was good, but for external ear and scalp-neck tumors it was poor. Multivariate analysis taking into account age and year of diagnosis showed the highest relative hazards (RH) for female lesions of the trunk (1.40) and male scalp-neck tumors (1.65), with the upper extremity used as reference (RH = 1.00). Except for lesions of the trunk, no significant differences in RH were found between the various sites after 4 years of observation.

Entities:  

Mesh:

Year:  1989        PMID: 2703003     DOI: 10.1016/0277-5379(89)90261-7

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  9 in total

Review 1.  Scalp junctional nevus with malignant transformation (melanoma) metastatic to parotid lymph node region, cervical lymph nodes and the back: a case report and review of literature.

Authors:  Zhuo-Ping Liang; Sheng-En Xu; Liang Jiang; Chong Zhao; Xiao-Qiang Sun; Gang Qin
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Tumor location predicts survival in cutaneous head and neck melanoma.

Authors:  Warren H Tseng; Steve R Martinez
Journal:  J Surg Res       Date:  2010-11-10       Impact factor: 2.192

3.  Melanoma of the ear: results of a cartilage-sparing approach to resection.

Authors:  Melissa A McCarty; Eric J Lentsch; Eric W Cerrati; Wayne K Stadelmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-30       Impact factor: 2.503

4.  Do Oncologic Outcomes From Head and Neck Versus Truncal and Extremity Melanoma Differ? A Single-Institution Single-Subspecialty Experience.

Authors:  Kirsten M Baecher; Michael K Turgeon; Caroline R Medin; Geetha Mahendran; Terrill M Flakes; Keith A Delman; Michael C Lowe
Journal:  Am Surg       Date:  2021-11-11       Impact factor: 0.688

Review 5.  Early detection and prevention of cutaneous malignant melanoma: emphasis on Swedish activities.

Authors:  U Ringborg; B Lagerlöf; M Broberg; E Månsson-Brahme; A Platz; M Thörn
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

6.  Primary Locations of Malignant Melanoma Lesions Depending on Patients’ Gender and Age

Authors:  Karolina Stanienda-Sokół; Natalia Salwowska; Martyna Sławińska; Katarzyna Wicherska-Pawłowska; Anna Lorenc; Dominika Wcisło-Dziadecka; Jerzy Wydmański; Wojciech Majewski
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

7.  Sentinel lymph node biopsy in head and neck cutaneous melanomas: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Yingyi Zhang; Chuanqi Liu; Zihuai Wang; Guonian Zhu; Yange Zhang; Yuyang Xu; Xuewen Xu
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

8.  Trends in tumour characteristics and survival of malignant melanoma 1960-84: a population-based study in Sweden.

Authors:  M Thörn; F Pontén; R Bergström; P Sparén; H O Adami
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

9.  Association Between Race/Ethnicity and Survival of Melanoma Patients in the United States Over 3 Decades: A Secondary Analysis of SEER Data.

Authors:  Melissa Ward-Peterson; Juan M Acuña; Mohammed K Alkhalifah; Abdulrahman M Nasiri; Elharith S Al-Akeel; Talal M Alkhaldi; Sakhr A Dawari; Sami A Aldaham
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.